Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation

Liver Transplantation

Volumn 17, Issue 8, 2011, Pages 943-954

  Zen, Chikako ^a   Zen, Yoh ^a   Mitry, Ragai R ^a   Corbeil, Denis ^b   Karbanová, Jana ^b,c   O'Grady, John ^a   Karani, John ^a   Kane, Pauline ^a   Heaton, Nigel ^a   Portmann, Bernard C ^a   Quaglia, Alberto ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIGEN; CELL ADHESION MOLECULE; CYTOKERATIN 19; EPITOPE; NERVE CELL ADHESION MOLECULE;

ABLATION THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CHEMOEMBOLIZATION; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; LIVER CELL CARCINOMA; LIVER NODULE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINDLE CELL;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; GLYCOPROTEINS; HUMANS; KERATIN-19; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEURAL CELL ADHESION MOLECULES; PEPTIDES; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 79960767350     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22314     Document Type: Article

References (59)

1. Lesurtel M, Müllhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA,. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6: 2644-2650. (Pubitemid 44571684)
2. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009; 72: 505-516.
3. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Accessed March 2011.
4. Marquardt JU, Thorgeirsson SS,. Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis 2010; 30: 26-34.
5. Spee B, Carpino G, Schotanus BA, Katoonizadeh A, Vander Borght S, Gaudio E, Roskams T,. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut 2010; 59: 247-257.
6. Sell S,. Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol 2002; 13: 419-424. (Pubitemid 36027146)
7. Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, et al. Hepatic 'stem cell' malignancies in adults: four cases. Histopathology 2003; 43: 263-271. (Pubitemid 37115060)
8. Haratake J, Hashimoto H,. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma. Liver 1995; 15: 9-15.
9. Wu PC, Lai VC, Fang JW, Gerber MA, Lai CL, Lau JY,. Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol 1999; 31: 965-966. (Pubitemid 29514235)
10. Libbrecht L, Roskams T,. Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol 2002; 13: 389-396. (Pubitemid 36027142)
11. Craig CE, Quaglia A, Selden C, Lowdell M, Hodgson H, Dhillon AP,. The histopathology of regeneration in massive hepatic necrosis. Semin Liver Dis 2004; 24: 49-64. (Pubitemid 38496048)
12. Corbeil D, Fargeas CA, Huttner WB,. Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein. Biochem Biophys Res Commun 2001; 285: 939-944. (Pubitemid 32918027)
13. Fargeas CA, Fonseca AV, Huttner WB, Corbeil D,. Prominin-1 (CD133) from progenitor cells to human diseases. Future Lipidol 2006; 1: 213-225.
14. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-2556. (Pubitemid 46890873)
15. Karbanová J, Missol-Kolka E, Fonseca AV, Lorra C, Janich P, Hollerová H, Jászai J, Ehrmann J, Kolár Z, Liebers C, Arl S, Subrtová D, Freund D, Mokry J, Huttner WB, Corbeil D,. The stem cell marker CD133 (prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 2008; 56: 977-993.
16. Dean M, Fojo T, Bates S,. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284. (Pubitemid 40488633)
17. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY,. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-1758. (Pubitemid 351380265)
18. Kohga K, Tatsumi T, Takehara T, Tsunematsu H, Shimizu S, Yamamoto M, et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol 2010; 52: 872-879.
19. Roskams T, Katoonizadeh A, Komuta M,. Hepatic progenitor cells: an update. Clin Liver Dis 2010; 14: 705-718.
20. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-1461. (Pubitemid 351346853)
21. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-1024.
22. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430. (Pubitemid 32844200)
23. Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, Chiriboga L, et al. The canals of Hering and hepatic stem cells in humans. Hepatology 1999; 30: 1425-1433.
24. Zhou H, Rogler LE, Teperman L, Morgan G, Rogler CE,. Identification of hepatocytic and bile ductular cell lineages and candidate stem cells in bipolar ductular reactions in cirrhotic human liver. Hepatology 2007; 45: 716-724. (Pubitemid 46450623)
25. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J,. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126: 2067-2078.
26. You H, Ding W, Rountree CB,. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010; 51: 1635-1644.
27. Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004; 39: 1739-1745. (Pubitemid 38702678)
28. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR,. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41: 809-818. (Pubitemid 40462943)
29. Quaglia A, Lehec SC, Hughes RD, Mitry RR, Knisely AS, Devereaux S, et al. Liver after hepatocyte transplantation for liver-based metabolic disorders in children. Cell Transplant 2008; 17: 1403-1414.
30. Zen Y, Harada K, Sasaki M, Tsuneyama K, Katayanagi K, Yamamoto Y, Nakanuma Y,. Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells: possible key phenomenon of hepatolithiasis. Am J Pathol 2002; 161: 1475-1484.
31. Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, Yano H R, Suzuki T, Matsuda M, Fujii H, Desmet VJ, Kojiro M, Roskams T,. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008; 47: 1544-1556. (Pubitemid 351702738)
32. Herber S, Biesterfeld S, Franz U, Schneider J, Thies J, Schuchmann M, et al. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Intervent Radiol 2008; 31: 768-777.
33. Morisco F, Stigliano R, Godfrey A, Leandro G, Patch D, Davidson B, et al. Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients. Dig Dis Sci 2008; 53: 1131-1137. (Pubitemid 351379849)
34. Marin HL, Furth EE, Olthoff K, Shaked A, Soulen MC,. Histopathologic outcome of neoadjuvant image-guided therapy of hepatocellular carcinoma. J Gastrointestin Liver Dis 2009; 18: 169-176.
35. Wong LL, Tanaka K, Lau L, Komura S,. Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant 2004; 18: 227-234. (Pubitemid 38744844)
36. Eguchi S, Hidaka M, Tomonaga T, Miyazaki K, Inokuma T, Takatsuki M, et al. Actual therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation. J Gastroenterol 2009; 44: 624-629.
37. Kim do Y, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Shin SW, Choo SW, Do YS, Rhee JC,. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol 2006; 12: 6992-6997. (Pubitemid 44834890)
38. Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K,. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol 1989; 23 (suppl): S4-S8. (Pubitemid 19073746)
39. Koda M, Maeda Y, Matsunaga Y, Mimura K, Murawaki Y, Horie Y,. Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res 2003; 27: 163-167. (Pubitemid 37322178)
40. Takada Y, Kurata M, Ohkohchi N,. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol 2003; 8: 332-335. (Pubitemid 37370261)
41. Nishihara Y, Aishima S, Kuroda Y, Iguchi T, Taguchi K, Asayama Y, et al. Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization. J Gastroenterol Hepatol 2008; 23: 1860-1868.
42. Kim YB, Park YN, Park C,. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 2001; 38: 160-166. (Pubitemid 32193630)
43. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-921. (Pubitemid 351506379)
44. Xiao EH, Li JQ, Huang JF,. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization. World J Gastroenterol 2004; 10: 190-194.
45. Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri R, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004; 78: 1780-1786. (Pubitemid 40041645)
46. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-416.
47. Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007; 133: 937-950. (Pubitemid 47374130)
48. Tan S, Chen JS, Sun LJ, Yao HR,. Selective enrichment of hepatocellular cancer stem cells by chemotherapy. J Int Med Res 2009; 37: 1046-1056.
49. Zen Y, Fujii T, Yoshikawa S, Takamura H, Tani T, Ohta T, Nakanuma Y,. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 2007; 170: 1750-1762. (Pubitemid 47339318)
50. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H,. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-824. (Pubitemid 44715858)
51. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007; 120: 1444-1450. (Pubitemid 46355378)
52. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-251. (Pubitemid 44049156)
53. Corbeil D, Röper K, Fargeas CA, Joester A, Huttner WB,. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001; 2: 82-91. (Pubitemid 32219860)
54. Roskams T,. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006; 25: 3818-3822. (Pubitemid 43980477)
55. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP,. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327-334. (Pubitemid 19112371)
56. Ahnen DJ, Kinoshita K, Nakane PK, Brown WR,. Differential expression carcinoembryonic antigen and secretory component during colonic epithelial cell differentiation and in colonic carcinomas. Gastroenterology 1987; 93: 1330-1338. (Pubitemid 17167276)
57. Singh A, Settleman J,. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
58. Desmet VJ,. The amazing universe of hepatic microstructure. Hepatology 2009; 50: 333-344.
59. Sell S, Leffert HL,. Liver cancer stem cells. J Clin Oncol 2008; 26: 2800-2805.